Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.

ABSTRACT: The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-effectiveness of benmelstobart (B) and anlotinib (A) plus etoposide and carboplatin (EC) as first-line treatment options for patients with ES-SCLC in China. From the perspective of Chinese healthcare system, a three-state partitioned survival model was employed. The cycle length was set at three weeks, and the time horizon of the study was set as lifetime horizon. Total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) as primary outputs of the m

SUBMITTER: Yan C 

PROVIDER: S-EPMC11933407 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature